Introduction
EPIX Pharmaceuticals is a clinical-stage biopharmaceutical company focused on small molecule drug discovery and development with pipeline of internally-discovered drug candidates currently in clinical development to treat diseases of the central nervous system and lung conditions. The company's lead product, Vasovist is marketed in 32 European nation and waiting for the approval in US.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
EPIX Pharmaceuticals' proprietary development program integrates computational methods with the medical chemistry which addresses the inefficiencies associated with the traditional methods of drug discovery.The company has four therapeutic product candidates in clinical trials for depression, Alzheimer's disease, cardiovascular disease and obesity. EPIX Pharmaceuticals derives its revenues from royalties, license and collaboration fees. The company's total revenues decreased from $12 million in 2004 to $4 million in 2006. EPIX Pharmaceuticals' total revenues are forecasted to expand by a CAGR of 66% over the period 2006-2010. The growth is attributed to the royalties, license, collaboration, and others, anticipating the company's business development deals and clinical developments of its early stage drug candidates.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization.
Report Highlights
[Studien Infos ausblenden]
